Venous Stents Market By Product Type (Self-Expanding Venous Stents, Balloon-Expandable Venous Stents, Drug-Eluting Venous Stents, Bare Metal Venous Stents, Others), By Material (Nitinol Stents, Stainless Steel Stents, Cobalt-Chromium Stents, Hybrid Materials, Others), By Indication (Chronic Venous Insufficiency (CVI), Deep Vein Thrombosis (DVT), Iliac Vein Compression Syndrome (May-Thurner Syndrome), Post-Thrombotic Syndrome (PTS), Venous Occlusion, Others), By End User (Hospitals, Specialty Vascular Clinics, Ambulatory Surgical Centers (ASCs), Academic & Research Institutes, Others), By Region and Companies — Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026–2035

Market Overview

The Global Venous Stents Market size is expected to be worth around US$ 2.8 Billion by 2035 from US$ 1.3 Billion in 2025, growing at a CAGR of 7.9% during the forecast period from 2026 to 2035. In 2025, North America led the market, achieving over 41.2% share with a revenue of US$ 0.53 Billion.

Venous stents are implantable mesh tubes placed endovascularly to support veins that are narrowed or occluded due to thrombosis or compression, improving blood flow and reducing chronic venous hypertension.

These devices are widely used in iliofemoral venous obstruction, especially in patients with chronic venous obstruction after deep vein thrombosis (DVT) and related complications. Venous stenting is increasingly integrated into interventional treatment strategies as an adjunct to angioplasty or catheter-based thrombectomy.

Venous thromboembolism (VTE), which includes DVT and pulmonary embolism (PE), remains a major public health concern. In the United States, up to 900,000 people are affected by VTE annually, and an estimated 60,000–100,000 die each year from these conditions. Epidemiological data indicate that approximately 1.5–2 per 1,000 adults experience a first VTE event per year in high-income regions.

Clinical studies show that venous stenting achieves high procedural success with long-term vessel patency: cumulative 5-year primary patency rates exceed 88%, with assisted primary and secondary patency rates near 92.5% and 98.9%, respectively, in dedicated cohorts.

These numbers underscore both the durability and clinical impact of stenting in symptomatic venous obstruction. Government public health sources continue to emphasise VTE prevention, early diagnosis, and evidence-based treatment to mitigate long-term sequelae and reduce mortality.

Key Takeaways

• Market Size: The Global Venous Stents Market size was US$ 1.3 billion in 2025. The market is estimated to grow to US$ 2.8 billion by 2035.
• Market Share: The Compound Annual Growth Rate (CAGR) of the market from 2026 to 2035 will be 7.9%.
• Product Type: Self-Expanding Venous Stents has the largest market share, accounting for 62.3% of total product type revenue.
• Material: Nitinol Stents leads the segment, accounting for 68.7% of total material segment revenue.
• Indication: Chronic Venous Insufficiency (CVI) leads the segment, accounting for 34.5% of total indication revenue.
• End User: Hospitals lead the segment, accounting for 61.2% of total end-user revenue.
• Regional Analysis: North America is the dominant regional market, accounting for 41.2% of global revenue.

Product Type Analysis

By product type, self-expanding venous stents dominate the venous stents market, accounting for 62.3% of the total share in 2025. Their leadership is driven by superior flexibility, continuous radial force, and the ability to adapt to the dynamic anatomy of venous vessels, particularly in iliofemoral and iliac vein interventions. These stents perform well under external compression and postural changes, making them the preferred choice in chronic venous obstruction and post-thrombotic conditions.

Balloon-expandable venous stents, representing 18.0% share, are mainly used in anatomically stable segments where precise placement and high radial strength are required. However, their comparatively lower flexibility limits broader adoption in tortuous venous anatomy. Bare-metal venous stents hold 11.0% share, supported by cost advantages and continued use in selected clinical settings, though concerns over restenosis restrict wider growth.

Drug-eluting venous stents, with a 5.0% share, remain an emerging segment, as clinical evidence for drug delivery benefits in venous circulation is still evolving. The others category (3.7%) includes niche and customised devices used in complex cases. Overall, product innovation continues to focus on enhancing durability, flexibility, and long-term venous patency.

Material Analysis

Based on material, nitinol stents dominate the venous stents market with a 68.7% share in 2025, reflecting their excellent balance of flexibility, shape memory, and biocompatibility. Nitinol’s superelastic properties allow stents to withstand venous compression while maintaining consistent radial force, which is critical for long-term vessel patency in large veins such as the iliac and femoral veins. These advantages have made nitinol the material of choice in most self-expanding venous stents.

Stainless steel stents account for 16.0% of the share, supported by their strength, cost-effectiveness, and long clinical history. However, their lower flexibility compared to nitinol limits use in complex venous anatomies. Cobalt-chromium stents, holding 8.0% share, offer high radial strength with thinner struts, but adoption remains moderate due to stiffness concerns in venous applications.

Hybrid materials, with a 6.0% share, combine different alloys to balance strength and flexibility and are gaining attention in next-generation device development. The other segment (1.3%) includes experimental and speciality materials. Overall, material selection is increasingly guided by long-term biocompatibility and sustained venous patency.

Indication Analysis

By indication, chronic venous insufficiency (CVI) leads the venous stents market, accounting for 34.5% of the total share in 2025. The dominance of CVI is driven by its high prevalence, ageing populations, and growing awareness of endovascular solutions for venous reflux and obstruction. Venous stenting is increasingly used to relieve outflow obstruction and reduce long-term complications such as pain, oedema, and venous ulcers.

Deep vein thrombosis (DVT) represents a significant segment, as post-thrombotic venous damage often requires stent placement to restore venous patency. Iliac vein compression syndrome (May-Thurner syndrome) has emerged as a key growth area due to improved diagnostic imaging and early interventional treatment. Post-thrombotic syndrome (PTS) continues to drive demand, given its chronic nature and the limited effectiveness of conservative therapy alone.

Additional segments include venous occlusion and others, covering congenital abnormalities and trauma-related obstruction. Rising vascular disease burden, combined with the shift toward minimally invasive treatments, is strengthening clinical adoption of venous stents across a broad range of indications.

End User Analysis

By end user, hospitals dominate the venous stents market with a 61.2% share in 2025, reflecting their high procedural volumes and access to advanced interventional infrastructure. Most complex venous stenting procedures, including those for chronic obstruction and post-thrombotic conditions, are performed in hospital settings where multidisciplinary vascular teams and imaging capabilities are readily available.

Speciality vascular clinics represent a growing segment, driven by the expansion of dedicated vein care centres and increasing outpatient management of venous disorders. These facilities benefit from focused expertise and streamlined patient pathways, particularly for elective venous interventions.

Ambulatory surgical centres (ASCs) are gradually gaining share as minimally invasive techniques reduce procedure times and hospital stays, making selected venous stenting cases suitable for outpatient care. Academic and research institutes contribute through clinical trials, technology evaluation, and training of interventional specialists, though their procedural volumes remain comparatively lower.

The others category includes rehabilitation and speciality care facilities with limited intervention capacity. Overall, end-user reflects the concentration of advanced venous interventions within hospital systems, alongside a gradual shift toward specialised and outpatient care models.

Key Market Segments

By Product Type

• Self-Expanding Venous Stents
• Balloon-Expandable Venous Stents
• Drug-Eluting Venous Stents
• Bare Metal Venous Stents
• Others

By Material

• Nitinol Stents
• Stainless Steel Stents
• Cobalt-Chromium Stents
• Hybrid Materials
• Others

By Indication

• Chronic Venous Insufficiency (CVI)
• Deep Vein Thrombosis (DVT)
• Iliac Vein Compression Syndrome (May-Thurner Syndrome)
• Post-Thrombotic Syndrome (PTS)
• Venous Occlusion
• Others

By End User

• Hospitals
• Speciality Vascular Clinics
• Ambulatory Surgical Centres (ASCs)
• Academic & Research Institutes
• Others

Driver

Rising post-thrombotic and iliac obstruction caseload

The strongest near-term demand driver is the enlarging treatable pool of patients progressing from deep vein thrombosis into chronic outflow obstruction and post-thrombotic syndrome. In addition, about one-third of patients experience recurrence within 10 years.

That matters commercially because venous stents are not sold into the full DVT pool, but into the narrower subgroup with symptomatic iliofemoral obstruction, recurrent swelling, ulcer risk, or failed conservative management, so even a modest rise in diagnosis and referral conversion expands procedure volumes disproportionately.

In practice, every 100 patients entering long-term DVT follow-up can generate a meaningful downstream intervention cohort once imaging confirms iliac compression, chronic obstruction, or post-thrombotic lesions, shifting revenue mix toward higher-value device-plus-procedure episodes rather than compression-only management.

Challenge

Imaging and IVUS Constraints Limiting Venous Stent Adoption

Appropriate venous stent use in 2026 remains constrained by complex case selection and uneven imaging workflows, where advanced cross-sectional imaging and intravascular ultrasound (IVUS) are not consistently available or integrated.

This creates a persistent friction that lowers procedure conversion rates by an estimated 10–15% and reduces potential market CAGR by about 0.9% points, despite rising venous thromboembolism incidence of up to 900,000 cases annually in the US.

Clinical outcomes remain strong, with meta-analyses showing 12-month primary patency rates of 80–85% for iliocaval stenting, but these depend heavily on accurate lesion assessment, landing zone planning, and sizing supported by IVUS and operator expertise.

IVUS penetration remains below 30–40% of venous procedures, contributing to underdiagnosis of iliac compression and post-thrombotic disease. This gap also extends the pre-procedural pathway by 7–14 days due to additional imaging and referrals, during which 5–10% of patients may be lost to follow-up or managed conservatively.

Strategically, improving outcomes requires wider IVUS adoption, standardised imaging protocols, and decision-support tools to reduce variability. Lab upgrades (USD 0.5–1.0 million) and structured training could raise IVUS use by 15–20 percentage points over 3–4 years, gradually reducing current inefficiencies and unlocking suppressed procedural volume.

Restraints

Narrow Indications and Conservative Care Limit Market Growth

A key restraint on venous stent demand is its structurally narrower indication base compared with arterial device markets. The primary validated use case remains symptomatic chronic iliofemoral venous obstruction, particularly post-thrombotic syndrome and selected nonthrombotic iliac vein lesions.

Current guideline interpretations still emphasise conservative management, careful clinical evaluation, and strict patient selection prior to considering stenting, which limits broader procedural expansion.

In practical terms, this creates a lower conversion rate from diagnosed chronic venous disease to intervention-eligible patients. Only a subset of patients progress from compression therapy, anticoagulation, and surveillance into invasive treatment, and variability in imaging thresholds, symptom scoring, and lesion-definition standards further slows decision-making.

In many centres, this can extend case-review cycles by 4 to 12 weeks and suppress referral-to-treatment conversion by an estimated 10–18% compared with more standardised algorithms. Commercially, these constraints reduce tray utilisation and salesforce productivity per account, while also delaying hospital capital expenditure decisions in lower-volume centres that cannot consistently support dedicated venous programs.

Collectively, this structural selectivity is estimated to pull around 1.7 % points from a hypothetical unconstrained CAGR for 2026–2030, reflecting slower procedural scaling despite steady underlying disease prevalence.

Opportunity

APAC LATAM Venous Stent Expansion Growth Opportunity

APAC and LATAM represent a meaningful upside opportunity for deep-vein stent adoption because current forecasts typically assume slower penetration and lower intervention rates than may ultimately materialise. Although chronic venous disease prevalence in these regions can approach or exceed 20% of adults, venous stenting is still largely concentrated in tertiary centres, with limited adoption in secondary city hospitals.

As urbanisation, obesity, and ageing accelerate in countries such as India, China, Brazil, and Mexico, a significant pool of underdiagnosed iliofemoral obstruction and post-thrombotic syndrome remains untapped. Even if only 1–2% of advanced cases were treated annually, this could translate into several hundred thousand additional procedures by the early 2030s, compared with current volumes likely in the low tens of thousands.

To capture this opportunity, manufacturers may need region-specific product strategies such as simplified SKUs, broader sizing, and cost-optimised systems, alongside tiered pricing 20–30% below US/EU levels. Hybrid or distributor-light models could help maintain gross margins around 60–65%. Expanding training hubs, secondary-city programs, and local KOL networks could accelerate adoption, potentially lifting global CAGR by around 1.5% points

Regional Analysis

In 2025, North America led the venous stent market, achieving over 41.2% of the market share with revenues of US$ 0.53 billion.

The market demonstrates strong regional variations, with North America at the forefront due to its advanced vascular care infrastructure, high awareness of chronic venous diseases, and the widespread availability of intravascular ultrasound (IVUS)-guided procedures.

The U.S. accounts for the majority of global demand, backed by favourable reimbursement frameworks and high procedure volumes for conditions such as iliocaval obstruction and post-thrombotic syndrome.

Europe ranks second, propelled by established interventional radiology networks and standardised treatment protocols. However, adoption rates vary within Europe, with distinct differences noted between Western and Eastern regions due to disparities in healthcare funding and access to advanced imaging techniques.

In contrast, the Asia-Pacific (APAC) region represents a high-growth market, driven by the increasing prevalence of venous diseases associated with ageing populations, urbanisation, and rising obesity rates. Nevertheless, market penetration remains largely confined to tertiary hospitals, while secondary and community centres are still underrepresented. This is mainly due to the limited availability of IVUS and uneven levels of specialist training.

Countries like China, India, and Japan are projected to drive future market expansion as healthcare infrastructure improves and awareness of procedures increases.Latin America (LATAM) is an emerging market with gradual adoption, primarily led by Brazil and Mexico, where private healthcare systems and urban hospital networks support initial uptake.

However, reimbursement constraints and limited access to advanced imaging technologies hinder broader market diffusion. Overall, while North America and Europe dominate current revenues, both APAC and LATAM present significant potential for long-term market growth.

Key Regions and Countries

North America

• The US
• Canada

Europe

• Germany
• France
• The U.K.
• Italy
• Spain
• Russia & CIS
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Middle East & Africa

• GCC
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Mexico
• Rest of Latin America

Key Player Analysis

Suppliers in the global venous stents market seek competitive advantage through nitinol stent design innovation, optimising radial force, flexibility, and crush resistance profiles specifically for the unique biomechanical demands of venous anatomy alongside dedicated venous stent regulatory approval programs that differentiate venous-specific devices from arterial stent platforms repurposed for venous applications.

Key strategic focus areas include dedicated chronic venous insufficiency and May Thurner syndrome indication clinical trial investment generating robust long term patency and symptom relief evidence supporting specialist vascular interventionist adoption.

Drug eluting venous stent platform development targeting improved long term patency rates over bare metal and nitinol alternatives, and ambulatory surgical center compatible delivery system development enabling venous stent procedures to migrate from inpatient hospital settings toward lower cost outpatient environments.

Companies continue investing in vascular interventionist training programs, intravascular ultrasound guidance protocol integration, and regulatory approval expansion across European CE Mark, US FDA, and Asia Pacific national regulatory frameworks to secure long-term institutional supply agreements with hospital vascular surgery departments, speciality vascular clinic networks, and ambulatory surgical centre procurement programs globally.

Top Key Players

• Abbott Laboratories
• Becton, Dickinson and Company
• Bentley InnoMed GmbH
• Boston Scientific Corporation
• Cook Medical
• Cordis Inc.
• W. L. Gore & Associates
• Plus Medica GmbH & Co. KG
• Medtronic plc
• MicroPort Scientific Corporation
• Optimed Medizinische Instrumente GmbH
• Koninklijke Philips N.V.
• Sinomed
• Terumo Corp.
• Zinas Medical
• Zylox-Tonbridge Medical Technology Co., Ltd.
• Merit Medical Systems Inc.
• Other Key Players

Recent Developments

• In January 2026, Boston Scientific Corporation received FDA clearance for its next-generation dedicated venous stent system for iliac vein compression syndrome treatment, targeting speciality vascular clinic and hospital interventional radiology institutional buyers across North American markets.
• In February 2026, Medtronic plc expanded its venous stent portfolio distribution across European speciality vascular clinics and hospital vascular surgery institutional buyers, targeting growing chronic venous insufficiency and post-thrombotic syndrome treatment demand.
• In March 2026, Cook Medical launched a dedicated venous stent training and proctorship program across North American and European vascular interventionist networks, targeting adoption among interventional radiologists and vascular surgeons managing complex venous occlusion cases.
• In May 2026, Abbott Laboratories secured a multi-year venous stent supply agreement with a leading European hospital vascular surgery network, covering institutional procurement for chronic venous insufficiency and deep vein thrombosis interventional treatment programs across its regional facilities.

Report Scope